DENELSKY STEPHEN J 4
4 · HARVARD BIOSCIENCE INC · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Harvard Bioscience (HBIO) Director Stephen Denelsky Buys 10,000 Shares
What Happened
Stephen J. Denelsky, a director of Harvard Bioscience, purchased 10,000 shares of the company's common stock in an open-market transaction on March 17, 2026 at $4.87 per share, a total purchase value of $48,700. This was a straight purchase (transaction code P), not an option exercise or award.
Key Details
- Transaction date and price: 2026-03-17, 10,000 shares @ $4.87 each (total $48,700).
- Shares owned after transaction: 21,000 beneficially owned (10,000 purchased + 11,000 restricted stock units).
- Notable footnotes: (1) The 11,000 RSUs fully vest on September 5, 2026. (2) A 10-for-1 reverse stock split on March 13, 2026 reduced previously reported 110,000 RSUs to 11,000; numbers in the filing reflect this split.
- Filing timeliness: Report filed 2026-03-18 for a 2026-03-17 transaction (timely filing).
Context
This is a direct open-market purchase by a company director, which increases his immediate stake; the RSUs are future ownership that vest later (Sept 5, 2026). Purchases are often considered more informative than routine sales, but the filing itself does not state the buyer’s motivation.
Insider Transaction Report
Form 4
DENELSKY STEPHEN J
Director
Transactions
- Purchase
Common Stock
[F1][F2]2026-03-17$4.87/sh+10,000$48,700→ 21,000 total
Footnotes (2)
- [F1]Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026.
- [F2]On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Signature
/s/ Stephen DeNelsky|2026-03-18